https://www.selleckchem.com/products/escin.html
1% and of chronic graft versus host disease was 21.4%. Overall survival was 80% and the event-free survival was 73.3%. The median follow-up of alive patients was 775 days (range 333 to 2077 d). Our experience shows encouraging outcomes using alternate donor HSCT for these patients from developing world.Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus-2. Patients with hematologic malignancies have been shown to have higher risk of mortality due to COVID-19 than reported in
Gefällt mir
Kommentar
Teilen
